Semi-mechanistic PK/PD modeling and simulation of irreversible BTK inhibition to support dose selection of tirabrutinib in subjects with RA.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2439
Abstract: Tirabrutinib is an irreversible, small-molecule Bruton's tyrosine kinase (BTK) inhibitor, which was approved in Japan (VELEXBRU® ) to treat B-cell malignancies and is in clinical development for inflammatory diseases. As an application of model-informed drug… read more here.
Keywords: tirabrutinib; semi mechanistic; model; btk ... See more keywords